Core Viewpoint - Lexaria Bioscience Corp. has successfully closed a registered direct offering of 2,661,600 shares of common stock at a price of $1.315 per share, alongside a concurrent private placement of unregistered warrants to purchase the same number of shares at an exercise price of $1.19 per share [1][2]. Group 1: Offering Details - The total gross proceeds from the offering amount to approximately $3.5 million, before deducting fees and expenses [2]. - The shares were offered under a "shelf" registration statement that became effective on January 30, 2025, and the offering was conducted via a prospectus [3]. - The warrants issued in the private placement are immediately exercisable and will expire five years from the effectiveness of the resale registration statement [1][4]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to advance research and development efforts, fund working capital, and support other general corporate purposes [2]. Group 3: Company Overview - Lexaria operates a patented drug delivery platform called DehydraTECH™, which enhances the absorption of various drugs through oral delivery [6]. - The company holds a robust intellectual property portfolio with 56 patents granted and additional patents pending worldwide [7].

Core Viewpoint - Lexaria Bioscience Corp. has announced a definitive agreement for a registered direct offering of 2,661,600 shares of common stock at a price of $1.315 per share, along with a concurrent private placement of unregistered warrants to purchase the same number of shares at an exercise price of $1.19 per share [1][2]. Group 1: Offering Details - The total gross proceeds from the offering are expected to be approximately $3.5 million before deducting fees and expenses [2]. - The offering is being conducted under a "shelf" registration statement that was declared effective by the SEC on January 30, 2025 [3]. - The warrants will be immediately exercisable and will expire five years from the effectiveness of the resale registration statement [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to advance research and development efforts, fund working capital, and cover other general corporate purposes [2]. Group 3: Company Background - Lexaria Bioscience Corp. specializes in drug delivery platforms, particularly its patented DehydraTECH™ technology, which enhances the absorption of drugs through oral delivery [6][7]. - The company holds a robust intellectual property portfolio with 56 patents granted and additional patents pending worldwide [7].

Core Viewpoint - The company has announced the acquisition of Arthrosi Therapeutics, pending regulatory clearance, which will enhance its gout treatment pipeline with the addition of Pozdeutinurad AR882, a next-generation URAT1 inhibitor [1][3]. Group 1: Acquisition Details - The acquisition aims to integrate Pozdeutinurad AR882 into the company's gout pipeline, which is expected to provide a novel best-in-class therapy for patients suffering from progressive gout [3][4]. - Pozdeutinurad has demonstrated clinically meaningful efficacy and a strong safety profile in several large Phase II trials, indicating its potential as a significant advancement in gout treatment [4]. Group 2: Strategic Rationale - The strategic rationale for the acquisition includes the opportunity to leverage Pozdeutinurad's unique properties as a once-daily oral medication, which could address unmet needs in the gout treatment market [4].

S-1/A 1 lxrp_s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. 333-290862 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-1 UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or Nevada 2000 20-2000871 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) ...

Revenue and Growth - Lexaria's total revenue for fiscal year 2025 increased by $241,645, or 52%, to $705,923 from $464,278 in fiscal year 2024[176] - Licensing revenue grew by $238,010, or 52%, to $696,000 in fiscal year 2025 compared to $457,990 in fiscal year 2024[176] Expenses and Losses - Research and development expenditures increased by $5,878,192, or 249%, to $8,238,757 in fiscal year 2025 from $2,360,565 in fiscal year 2024[178] - The net loss from operations increased by $6,102,780 to $11,911,434 for the year ended August 31, 2025, compared to $5,808,654 for the year ended August 31, 2024[174] - General and administrative expenses increased by $493,162, or 13%, to $4,345,183 in fiscal year 2025 from $3,852,021 in fiscal year 2024[183] - Other Income/(Loss) for fiscal year 2025 decreased by $24,827, or 45%, resulting in a loss of $30,697, down from a loss of $55,524 in fiscal year 2024[186] - The Company has accumulated net losses of $63.5 million since entering the bioscience sector, with approximately $11.9 million and $5.8 million incurred in the past two fiscal years[187] Cash Flow and Financial Position - As of August 31, 2025, the Company had cash on hand of approximately $1.8 million to settle $1.5 million in current liabilities, raising substantial doubt about its ability to continue as a going concern[193] - The Company's working capital decreased by approximately $4.8 million, with current assets at $3,468,345 and current liabilities at $1,493,463 as of August 31, 2025[195] - Net cash used in operating activities was approximately $10.5 million for the year ended August 31, 2025, compared to $5.0 million during the same period in 2024, primarily due to an increase in net loss[197] - Net cash provided by financing activities totaled approximately $6.0 million from the sale of common shares during the fiscal year[199] Strategic Initiatives and Future Outlook - Lexaria anticipates a decrease in revenue from technology licensing in fiscal 2026 due to the expiration of its license agreement with Premier[177] - The company is exploring equity financing arrangements and strategic corporate partnerships to support its drug investigations[173] - The Company intends to form industry partnerships for later stage clinical development, which is expected to be a multi-year process[188] Research and Development - Lexaria completed two human pilot studies and an Australian clinical trial investigating DehydraTECH infused GLP-1, GIP, and CBD formulations during the fiscal year[169] - The company was granted a total of six new patents during fiscal 2025, including patents for treating epilepsy and diabetes[165] Share Issuance - The Company issued 2,000,000 shares of common stock at $1.00 each in a registered direct offering, generating net proceeds of $1.7 million[189] - On September 26, 2025, the Company agreed to sell 2,666,667 shares of common stock at a purchase price of $1.50 per share, resulting in net proceeds of $3.5 million[191] Impairment and Losses - The Company recognized an impairment loss of $247,364 related to abandoned patent applications for the year ended August 31, 2025, compared to $57,836 for the year ended August 31, 2024[185]

Core Insights - Lexaria Bioscience Corp. has extended its Material Transfer Agreement (MTA) with PharmaCO until April 30, 2026, to allow for the review of data from an Australian study [2][3] - The MTA enables continued collaboration and strategic planning discussions between Lexaria and PharmaCO's clinical development team [2] - Lexaria's DehydraTECH™ technology aims to enhance drug delivery through oral administration, improving bio-absorption and reducing side effects [4] Summary by Sections Material Transfer Agreement Update - The MTA originally signed on September 4, 2024, has been extended to accommodate PharmaCO's review of Lexaria's Australian study data [2] - This extension allows both parties to maintain their relationship and keep the temporary exclusive license active [2] Pre-Clinical Studies and Future Expectations - Initial pre-clinical studies examining pharmacokinetics in animals have been completed [3] - Lexaria is awaiting PharmaCO's review of safety, pharmacokinetic, and efficacy data from its independent Australian human clinical study, with final results expected by the end of Q4 2025 [3] About Lexaria and DehydraTECH - DehydraTECH™ is a patented drug delivery platform that enhances the absorption of various drugs through oral delivery [4] - Lexaria holds a strong intellectual property portfolio with 54 patents granted and additional patents pending globally [4]

As filed with the Securities and Exchange Commission on October 14, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2000 20-2000871 (I.R.S. Employer Identification No.) 100-740 McCurdy Road Kelowna, British Colum ...

Core Insights - Lexaria Bioscience Corp. has engaged a global life science business development advisory firm to enhance its business development activities and identify collaborative opportunities in the pharmaceutical and biotechnology sectors [3][4][6] - The company has been awarded four new patents, expanding its intellectual property portfolio and supporting its strategic R&D programs in various therapeutic areas [9][10] Business Development - Lexaria has validated its DehydraTECH technology for applications in diabetes control, weight loss, hypertension, seizure disorders, anti-viral treatments, and hormone replacement [2] - The recent equity financing raised $4.0 million, enabling Lexaria to expand its strategic outreach and R&D activities into 2026 [4][7] - The engagement of the advisory firm is expected to facilitate new outreach activities and strengthen business connections within the pharmaceutical industry [3][6] Research and Development - Lexaria's R&D programs are designed to evolve alongside its business development efforts, with a focus on building strategic connections in the pharmaceutical and biotechnology sectors [5][6] - The company anticipates results from a Phase 1b Australian study in the GLP-1 sector, which is expected to demonstrate patient safety and efficacy with DehydraTECH processing [8] - The newly awarded patents cover therapeutic applications in diabetes, hypertension, seizure disorders, and antiviral treatments, enhancing the company's R&D capabilities [9][10]

Core Points - Lexaria Bioscience Corp. has closed a registered direct offering of 2,666,667 shares at a price of $1.50 per share, raising approximately $4.0 million before expenses [1][3] - The company also issued unregistered warrants for the purchase of an equal number of shares at an exercise price of $1.37, which are immediately exercisable and expire in five years [1][2] - The financing aims to enhance Lexaria's options for its 2026 R&D and business development plans, focusing on executing research initiatives that drive intellectual property and shareholder value [2] Financial Details - The gross proceeds from the offering were approximately $4.0 million, which will be used for working capital and general corporate purposes [3] - The shares were offered under a "shelf" registration statement effective since January 30, 2025, and the offering was conducted in compliance with SEC regulations [4] Warrants and Securities - The warrants were issued in a private placement and are not registered under the Securities Act, limiting their sale in the U.S. without an effective registration statement [5] - The company emphasizes that the offering does not constitute an offer to sell or solicit any offers to buy the securities in jurisdictions where such actions would be unlawful [6] Technology and Intellectual Property - Lexaria's DehydraTECH™ platform enhances drug delivery through oral administration, improving bio-absorption and reducing side effects [7] - The company holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide [7]

Core Viewpoint - Lexaria Bioscience (NASDAQ:LEXX) is experiencing a decline in stock price following the announcement of a direct offering of 2,666,667 shares at a price of $1.50 per share, which is expected to generate gross proceeds of approximately $4.0 million [1] Group 1 - The company announced a sale of 2,666,667 shares with a par value of $0.001 per share [1] - The offering price is set at $1.50 per share [1] - Gross proceeds from the offering are anticipated to be around $4.0 million [1]